Management ChangeJun 8, 2026, 12:56 PM
Ionis Appoints Ludwig Hantson to Board of Directors
AI Summary
Ionis Pharmaceuticals announced the appointment of Ludwig N. Hantson, Ph.D., a global biopharmaceutical leader with over 30 years of experience, to its Board of Directors, effective June 4, 2026. This strategic addition is expected to support the company's upcoming commercial launches and scaling operations. The company also noted the prior appointment of Peter N. Reikes and the retirement of two long-serving directors. Additionally, at its Annual Meeting, stockholders approved several proposals, including amendments to increase shares authorized under the 2011 Equity Incentive Plan by 9,500,000 and the 2000 Employee Stock Purchase Plan by 750,000.
Key Highlights
- Ionis appointed Ludwig N. Hantson, Ph.D., with over 30 years of biopharmaceutical leadership, to its Board of Directors.
- Peter N. Reikes was also appointed to the board, while Joseph Wender and Lynne Parshall retired.
- Stockholders approved an amendment to the 2011 Equity Incentive Plan, increasing authorized shares by 9,500,000 to 52,000,000.
- Stockholders approved an amendment to the 2000 Employee Stock Purchase Plan, increasing authorized shares by 750,000.
- Spencer R. Berthelsen and Joan E. Herman were elected as directors until the 2029 Annual Meeting.
- Stockholders approved the advisory vote on executive officer compensation.
- Ernst & Young LLP was ratified as the independent auditor for the 2026 fiscal year.
Price Impact
More from IONS